BRIEF published on 04/05/2024 at 10:22, 1 year 11 months ago APONTIS PHARMA conclut un accord de distribution et de commercialisation de cinq ans avec Novartis pour des médicaments contre l'asthme Prévisions Financières Industrie Pharmaceutique PHARMA APONTIS Médicaments Contre L'asthme Novartis
PRESS RELEASE published on 04/05/2024 at 10:17, 1 year 11 months ago APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast APONTIS PHARMA partners with Novartis for asthma medications distribution and marketing, raising forecast for 2024 financial year Distribution Agreement APONTIS PHARMA Asthma Medications Novartis Forecast Increase
BRIEF published on 04/05/2024 at 10:15, 1 year 11 months ago APONTIS PHARMA AG Enhances Forecast Following Agreement with Novartis APONTIS PHARMA AG Financial Growth Forecast Upgrade Novartis Agreement Asthma Medications
BRIEF published on 04/05/2024 at 10:15, 1 year 11 months ago APONTIS PHARMA AG améliore ses prévisions suite à un accord avec Novartis Croissance Financière APONTIS PHARMA AG Mise À Niveau Des Prévisions Accord Novartis Médicaments Contre L'asthme
PRESS RELEASE published on 04/05/2024 at 10:10, 1 year 11 months ago EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications APONTIS PHARMA AG raises forecast following agreement with Novartis for asthma medications Forecast Raise Financial Outlook APONTIS PHARMA AG Novartis Agreement Asthma Medications
BRIEF published on 03/28/2024 at 07:35, 1 year 11 months ago APONTIS PHARMA Anticipates Profitable Growth in 2024 After Restructuring APONTIS PHARMA Single Pill Combinations Financial Results 2023 Profitable Growth 2024 Restructuring Program
BRIEF published on 03/28/2024 at 07:35, 1 year 11 months ago APONTIS PHARMA prévoit une croissance rentable en 2024 après sa restructuration Résultats Financiers 2023 PHARMA APONTIS Croissance Rentable 2024 Combinaisons De Pilules Uniques Programme De Restructuration
PRESS RELEASE published on 03/28/2024 at 07:30, 1 year 11 months ago APONTIS PHARMA expects profitable growth again in 2024 APONTIS PHARMA expects profitable growth in 2024 with sales forecasted to rise to EUR 41.7 million and positive EBITDA of EUR 1.8 million. Performance and efficiency improvements drive future growth EBITDA Profitable Growth APONTIS PHARMA Sales Forecast Efficiency Improvements
PRESS RELEASE published on 02/09/2024 at 10:52, 2 years 1 month ago Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen APONTIS PHARMA AG hat ein Strategie-Update gegeben und finanzielle Details aus der Restrukturierung bekannt gegeben, was zu einer Reduktion der Break Even-Schwelle führt APONTIS PHARMA AG Strategie-Update Restrukturierung Finanzielle Details Break Even-Schwelle
PRESS RELEASE published on 02/06/2024 at 07:30, 2 years 1 month ago APONTIS PHARMA successfully completes performance and efficiency improvement program APONTIS PHARMA successfully completes performance and efficiency improvement program, reducing headcount and expenses. New go-to-market approach for Single Pill combinations to start on 1 March 2024 Pharmaceutical Company Efficiency APONTIS PHARMA Performance Improvement Single Pill Combinations
Published on 03/26/2026 at 21:00, just now Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 16:20, 4 hours 40 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 8 hours ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 8 hours ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 20:48, 12 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 1 hour 40 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 1 hour 51 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 1 hour 51 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 2 hours 43 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 2 hours 43 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 3 hours ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
